“Post-polypectomy surveillance accounts for approximately 25% of the colonoscopies in adults over 50 years of age in Western countries,” according to Dr Paul Brouzeng (CHU Limoges, France) [1]. The research team aimed to evaluate the appropriateness of a delayed endoscopic follow-up in these patients. They performed a retrospective, multicentre, international study, including patients who underwent polypectomy for benign lesions, were followed up for at least 3 years, and had undergone at least 1 SC. The investigators compared 2 groups: an early SC (<24 months) followed by a late SC (>24 months; n=643), and a group that had only received a late SC (n=135).
The rate of advanced adenoma at the first SC was 3.9% in the ‘early group’ and 6.7% in the ‘late group’, representing a non-significant difference (P=0.167). 3 cases of colorectal cancer were detected, all in the ‘early group’. The investigators also assessed risk factors for metachronous advanced neoplasia and found that the number of non-large adenomas or serrated lesions at index colonoscopy was the only significant predictor (OR 1.16; 95% CI 1.07-1.27; P<0.01), whereas older age had a modestly protective effect (OR 0.97; P<0.05).
“The rate of advanced neoplasia following colorectal ESD for benign lesions is low, with no significant difference between early and late surveillance strategies,” concluded Dr Brouzeng. “Extending surveillance intervals may therefore be a safe option to reduce the colonoscopy burden, providing both economic and logistic benefits without compromising colorectal cancer prevention.”
- Brouzeng P, et al. Safety and efficacy of extended surveillance intervals following colorectal ESD: an international multicentre study. LB12, Colorectal ESD: The better way? UEG Week, 4-7 October 2025, Berlin, Germany.
Medical writing support was provided by Robert van den Heuvel.
Copyright ©2025 Medicom Publishing Group
Posted on
Previous Article
« Different outcomes of AI-read vs human-read endoscopies in the TITRATE study Next Article
PuraStat is effective and safe in real-world radiation proctopathy »
« Different outcomes of AI-read vs human-read endoscopies in the TITRATE study Next Article
PuraStat is effective and safe in real-world radiation proctopathy »
Table of Contents: UEGW 2025
Featured articles
Relapse rate and risk factors after anti-TNF withdrawal in UC
Reducing TME burden with a risk-stratified approach in early rectal cancer
Different outcomes of AI-read vs human-read endoscopies in the TITRATE study
Online First
Sugar-sweetened and non-sugar-sweetened beverages linked to MASLD risk
Rabeprazole may be the preferred high-dose PPI in severe eGERD
Promising signs from a novel Helicobacter Pylori vaccine
Relapse rate and risk factors after anti-TNF withdrawal in UC
TURN2: Well-prepared FMT shows efficacy in UC
Can vedolizumab simplify the management of checkpoint inhibitor-induced enterocolitis?
GLISTEN: Linerixibat meets primary endpoint in PBC-associated cholestatic pruritus
Reducing TME burden with a risk-stratified approach in early rectal cancer
PuraStat is effective and safe in real-world radiation proctopathy
Extended surveillance intervals after colorectal ESD may be safe and feasible
Different outcomes of AI-read vs human-read endoscopies in the TITRATE study
Can SIK3 inhibition become the Holy Grail for autoimmune diseases?
Mufemilast advances to phase 3 following positive phase 2 results in UC
High-dose obefazimod is efficacious in UC regardless of prior therapy exposure
Endoscopic approach preferred over surgery in gastric outlet syndrome
Related Articles
September 10, 2020
Bariatric surgery associated with long-term kidney function improvement
October 23, 2019
Global burden of digestive diseases reveals alarming trends
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com
